CL7 1.5 mg Pill - yellow capsule/oblong, 18mm
Pill with imprint CL7 1.5 mg is Yellow, Capsule/Oblong and has been identified as Rivastigmine Tartrate 1.5 mg. It is supplied by Macleods Pharmaceuticals Limited.
Rivastigmine is used in the treatment of Alzheimer's Disease; Parkinson's Disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 1.5 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for CL7 1.5 mg
Rivastigmine Tartrate
- Imprint
- CL7 1.5 mg
- Strength
- 1.5 mg
- Color
- Yellow
- Size
- 18.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Cholinesterase inhibitors
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Macleods Pharmaceuticals Limited
- National Drug Code (NDC)
- 33342-0089
- Inactive Ingredients
-
magnesium stearate,
microcrystalline cellulose,
silicon dioxide,
gelatin,
titanium dioxide,
sodium lauryl sulfate,
ferric oxide red,
ferric oxide yellow,
hypromelloses
Note: Inactive ingredients may vary.
More about rivastigmine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (39)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: cholinesterase inhibitors
Patient resources
- Rivastigmine drug information
- Rivastigmine transdermal
- Rivastigmine (Oral) (Advanced Reading)
- Rivastigmine (Transdermal) (Advanced Reading)
- Rivastigmine Capsules
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.